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Over recent decades, the numerous coronary revascularisa-
tion procedures performed either by percutaneous coronary
intervention (PCI), or coronary bypass surgery has led to
an increasing number of patients who are no longer eligible
for additional revascularisation procedures. This number of
patients is expected to rise even further in view of an in-
crease in life expectancy in patients with coronary artery
disease.
In a recent issue of the Netherlands Heart Journal, the
investigators from the University Medical Center Utrecht
report interesting findings on the use of a coronary sinus
device in patients with refractory angina in whom there
were no options for conventional revascularisation proce-
dures [1]. This device is a balloon expandable stainless
steel stent that creates a focal stenosis in the coronary sinus
leading to an increase in coronary venous pressure.
The principle of improving myocardial perfusion by el-
evating coronary venous pressure was introduced as early
as 1954 when the coronary sinus was partially ligated in
patients with angina pectoris [2]. The publication of the
COSIRA trial has rekindled interest in the principle of en-
hancing coronary venous pressure for relief of angina by
means of a stent implantation. This prospective multicentre
double-blind sham-controlled trial evaluated coronary sinus
stent implantation in patients with refractory angina and
demonstrated both symptomatic improvement and an im-
provement in quality of life over a six-month follow-up pe-
riod [3]. The study from Abawi et al. [1] evaluated the same
coronary sinus stent device as in the COSIRA trial. It is
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a retrospective analysis of a consecutive series of 23 patients
with refractory angina for whom there were no options for
coronary revascularisation. In contrast to the COSIRA trial,
there were no formal exclusion criteria except the presence
of ischaemia related to the perfusion territory of the right
coronary artery. Documentation of myocardial ischaemia
was a prerequisite and was done either by bicycle stress
electrocardiography, dobutamine stress echocardiography,
single-photon emission computed tomography (SPECT), or
stress magnetic resonance imaging. This is in contrast to the
COSIRA trial which only included patients who had under-
gone positive dobutamine stress echocardiography. The out-
come of the present study was anginal status, evaluated by
a questionnaire, while evaluation of myocardial ischaemia
was not repeated. An improvement in anginal status was
documented in 74% of the patients which is in line with the
observations of previous non-randomised trials, as well as
the COSIRA trial, all of which used the same stent device
as in the present study.
The implantation of the balloon expandable stent into
the coronary sinus creates a focal stenosis and, as a result,
an increase in coronary venous pressure. It is remarkable
that none of the aforementioned clinical studies verified this
supposed increase in venous pressure by using either fluid-
filled catheters or pressure guidewires. There are several
postulated mechanisms that may explain the improvement
in angina status, although they have not been proven in
the clinical setting. First, the increase in venous pressure
may lead to the enhancement of collateral blood flow to
ischaemic regions [4, 5]. Additionally, the increase of coro-
nary sinus back pressure may lead to a redistribution of flow
to the endocardial regions, which are prone to ischaemia, by
dilatation of the subendocardial capillaries [5, 6]. Finally,
myocardial perfusion may also be improved by neovascu-
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larisation as has been shown in a canine experimental model
[7].
Coronary back pressure can also be increased intermit-
tently and this modification of the technique has recently
been tested in the setting of reperfusion in primary PCI [8].
It has been suggested that this intermittent balloon coro-
nary sinus occlusion may be beneficial due to other mecha-
nisms such as re-opening of the microvasculature, washout
of toxic metabolites and activation of vascular regeneration
[9]. Being one of the pioneers of intermittent coronary si-
nus occlusion in the setting of primary PCI, I have always
been reluctant to use a flow-limiting device for refractory
angina, due to the risk of thrombotic occlusion of this rel-
atively large device in a low pressure environment. It is
remarkable that this serious complication did not occur in
previous clinical studies or in the present study, where dual
antiplatelet therapy (aspirin and clopidogrel) was only given
for one month.
The authors are to be commended for conducting this
trial and for their tenacity in using this device in patients
with refractory angina. Previous clinical trials and the
promising results of the present study encourage further
exploration of this novel mode of therapy for the increas-
ing number of patients who are not eligible for current
revascularisation therapies. The relative simplicity of the
implantation techniques and their documented efficacy and
safety warrants further evaluation in larger sized trials to
verify these interesting findings. We must await the long-
term clinical outcome of the patients enrolled in the tri-
als, including their safety, to show if implantation of this
coronary sinus device adds to the armamentarium of the
coronary interventionalist for the treatment of patients with
refractory angina who are no longer candidates for current
coronary revascularisation procedures.
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